Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Feb;60(1):33-39.
doi: 10.4103/nmj.NMJ_12_19.

Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria

Mustapha Gidado  1 , Nkiru Nwokoye  1 , Chidubem Ogbudebe  1 , Bassey Nsa  1 , Peter Nwadike  1 , Prisca Ajiboye  1 , Rupert Eneogu  1 , Sani Useni  1 , Emeka Elom  2 , Adebola Lawanson  2
Affiliations

Assessment of GeneXpert MTB/RIF Performance by Type and Level of Health-Care Facilities in Nigeria

Mustapha Gidado et al. Niger Med J. 2019 Jan-Feb.

Abstract

Setting: Nigeria adopted GeneXpert MTB Rif as a primary diagnostic tool were available and accessible since 2016. The current geographical coverage of GeneXpert machines by LGAs stands at 48%, with a varied access and utilization.

Objectives: To assess the association between the type and level of health facilities implementing GeneXpert MTB/Rif and performance outcome of the machines in Nigeria.

Study design: Retrospective secondary data analysis of GeneXpert performance for 2017 from GXAlert database. The independent variables were type and levels of health care facilities, and dependent variables were GeneXpert performance (utilization, successful test, error rates, MTB detected, and Rifampicin resistance detected).

Results: Only 366 health care facilities are currently implementing and reporting GeneXpert performance, the distribution is 86.9% and 13.1% public and private health care facilities respectively, and only 6.3% of the facilities are primary health care. Of 354,321 test conducted in 2017, 91.5% were successful, and among unsuccessful test 6.8% were errors. The yield was 16.8% MTB detected (54,713) among which 6.8% had Rif resistance. The GeneXpert utilization rate was higher among private health care facilities (55.8%) compared to 33.3% among public health care facilities. There was a statistically significant difference in the number of successful test between public and private health facility-based machines as determined by one-way ANOVA (F(1,2) = 21.81, P = 0.02) and between primary, secondary and tertiary level health facility-based machines (F(1,2) = 41.24, P < 0.01).

Conclusion: Nigeria with very low TB coverage should rapidly scale-up and decentralize GeneXpert services to the private sector.

Keywords: GeneXpert utilization; private health facility; public health facility.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2017. pp. 180–2.
    1. Federal Ministry of Health. Department of Public Health: National TB and Leprosy Annual Report. Federal Ministry of Health. 2016
    1. World Health Organization. Policy Statement: Automated real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. 2011 - PubMed
    1. World Health Organization. Global Tuberculosis Control Report. Geneva: World Health Organization; 2012.
    1. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: What lessons have we learnt and how can we do better? Eur Respir J. 2016;48:516–25. - PMC - PubMed